60 Degrees Pharmaceuticals, Inc. stock analysis
Want to see SXTP full AI Analyst Report?
60 Degrees Pharmaceuticals, Inc. (SXTP) Stock Price & Analysis
SXTP Stock Chart & Stats
- Day’s Range
- $0.46 - $0.50
- 52-Week Range
- $0.46 - $8.62
- Previous Close
- $0.50
- Volume
- N/A
- Average Volume (3M)
- 677.36K
- Market Cap
- $2.24M
- Enterprise Value
- $13.06M
- Total Cash (Recent Filing)
- $306.19K
- Total Debt (Recent Filing)
- $208.50K
- Price to Earnings (P/E)
- ―
- Beta
- 1.77
- Next Earnings
- Mar 26, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Existing Commercial Product
ARAKODA gives the company an existing commercial product and an established malaria-focused platform rather than a portfolio consisting solely of unapproved candidates. Its measurable revenue and gross profit can support commercial learning while the company pursues additional indications.
Babesiosis Clinical Evidence
The expanded-access results provide clinically relevant evidence supporting tafenoquine in relapsing babesiosis, including molecular results consistent with cure in most assessed patients. If reinforced by the randomized study, this evidence could strengthen the regulatory case and expand the product opportunity.
Low Current Debt
Current debt is low and leverage is moderate, which limits near-term interest and repayment pressure relative to a more heavily indebted structure. This gives management some balance-sheet flexibility to direct available resources toward development and commercialization, despite broader capital constraints.
Bears Say
Small, Declining Revenue Base
Revenue remains too small to support the company’s cost structure, while the latest decline indicates that commercial traction is not yet consistently expanding. Deep operating and net losses leave the business dependent on future product growth, successful development, or additional financing.
Persistent Cash Burn
Cash outflows are many times larger than current revenue and closely track reported losses, showing that the funding requirement reflects recurring operating economics rather than mainly non-cash charges. Continued development and operations therefore depend on securing capital or materially improving cash generation.
Nasdaq Delisting Risk
The delisting decision creates a significant structural risk for the company’s market access and financing capacity over the next several months. Although a hearing is pending, the prior reverse splits and failure to qualify for another compliance period make the listing outcome an important execution overhang.
60 Degrees Pharmaceuticals, Inc. News
60 Degrees expands vector-borne disease research portfolio with USM
60 Degrees Pharmaceuticals (SXTP) announced expansion of its vector-borne disease research portfolio through a sponsored research agreement with The University of Southern Mississippi, or USM, to assess the therapeutic potential
60 Degrees’ tafenoquine shows improvement in all five babesiosis patients
60 Degrees Pharmaceuticals (SXTP) announced clinical and molecular results from the first five patients to complete treatment with tafenoquine-containing combination regimens in its expanded access study of relapsing babesiosis in
SXTP FAQ
What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?
What is 60 Degrees Pharmaceuticals, Inc.’s market cap?
When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?
How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?
Is 60 Degrees Pharmaceuticals, Inc. overvalued?
Does 60 Degrees Pharmaceuticals, Inc. pay dividends?
What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?
How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?
What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Geoffrey Stuart Dow
- Employees
- 3
- Website
- www.60degreespharma.com
- Address
- 1025 Connecticut Avenue NW, Washington, DC, 20036, US
60 Degrees Pharmaceuticals, Inc. (SXTP) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |













